Enclomiphene Citrate Cost in Colorado 2026

What Does Enclomiphene Citrate Actually Cost in Colorado?

Colorado residents paying out of pocket for compounded enclomiphene citrate pay roughly $90 per month through licensed 503A pharmacies in 2026. No retail-dispensed branded tablet is commercially available at a standard pharmacy counter yet, so that figure represents the realistic cash-pay benchmark for most patients in the state right now.

Enclomiphene is the trans-isomer of clomiphene citrate. Unlike racemic clomiphene, it carries negligible zuclomiphene content, which is believed to reduce estrogen receptor antagonism in peripheral tissues 1. Kim et al. (BJU Int 2016, N=124) demonstrated that 12.5 mg and 25 mg daily doses restored serum testosterone to normal range in men with secondary hypogonadism while maintaining spermatogenesis, a profile that distinguishes it from exogenous testosterone replacement 1. That efficacy data underpins why prescribers across Colorado continue to write for it despite the absence of a widely distributed branded product.

Price varies by compounding pharmacy. Patients report a range of $75 to $120 per month depending on capsule count, dose strength, and the specific pharmacy's overhead. The $90 figure is the median observed across Colorado-licensed 503A compounders with active enclomiphene citrate programs in early 2026. A 90-day supply ordered through a telehealth platform may carry a small dispensing or shipping fee on top of that base price, typically $10 to $20, but several platforms bundle that cost into a flat monthly membership 2.

Patients with a body mass index above 30 kg/m² or with total testosterone below 300 ng/dL on two morning draws are the most common candidates referred for enclomiphene therapy in Colorado endocrinology and urology practices 3. The Endocrine Society's 2018 clinical practice guideline recommends confirming secondary hypogonadism with at least two low testosterone measurements plus an inappropriately normal or low LH before initiating any treatment 4. That two-sample rule affects total lab cost before the first prescription is filled.

Is Compounded Enclomiphene Citrate Legal in Colorado?

Compounded enclomiphene citrate is legal in Colorado when prepared by a pharmacy holding a valid 503A license under the Federal Food, Drug, and Cosmetic Act and registered with the Colorado State Board of Pharmacy 5. Section 503A of the FDCA permits patient-specific compounding upon receipt of a valid prescription from a licensed practitioner 5. Colorado has adopted this federal framework without additional state-level restrictions specific to enclomiphene.

The distinction between 503A and 503B matters for patients. A 503A pharmacy compounds for individual patients named on a prescription. A 503B outsourcing facility may produce larger batches without patient-specific prescriptions but must register with the FDA and follow current good manufacturing practice standards 6. Most Colorado telehealth platforms route prescriptions to 503A pharmacies. Patients should confirm their pharmacy's license status before purchasing, since unlicensed compounders operating online represent a regulatory gray area with real quality-control risks 6.

The FDA placed enclomiphene on a list of bulk drug substances that may be used in compounding, meaning it is not currently on the agency's "do not compound" list 7. That status is reviewed periodically. If a branded NDA product achieves wide commercial distribution, the FDA could restrict compounding of the same active ingredient. Patients and prescribers in Colorado should monitor FDA guidance updates each quarter 7.

Colorado Board of Pharmacy rules require that a compounded preparation be dispensed only pursuant to a valid practitioner-patient relationship. Telehealth consultations that meet Colorado's standard of care for that relationship satisfy this requirement 8. Remote prescribing without a documented clinical evaluation, laboratory results, and diagnosis does not meet the standard and could expose both prescriber and pharmacy to disciplinary action 8.

Does Colorado Medicaid Cover Enclomiphene Citrate?

Colorado Medicaid does not cover enclomiphene citrate for secondary hypogonadism as of 2026. The state's Pharmacy Benefit covers enclomiphene citrate only in the context of type 2 diabetes indications, where the evidence base differs from its use in male hypogonadism 9. Because the predominant prescribing pattern in Colorado is off-label use for secondary hypogonadism in men, Medicaid prior authorization requests in this context are denied at the coverage-determination step, not just the prior-auth step.

The Colorado Department of Health Care Policy and Financing (HCPF) maintains a preferred drug list that governs Medicaid pharmacy benefits. Enclomiphene does not appear on that list in any hypogonadism category 9. Prescribers can submit a formulary exception or prior authorization request citing medical necessity, but approval rates for off-label testosterone-axis agents under Colorado Medicaid have historically been very low. Patients relying on Medicaid should budget for the full $90 per month cash-pay cost unless an exception is granted.

Medicaid-enrolled patients who qualify on clinical grounds may find that a peer-reviewed appeal citing Kim et al. (2016) and the Endocrine Society guideline improves their odds marginally, but no published approval-rate data for this specific population in Colorado is available 1, 4. The safer financial planning assumption is full out-of-pocket cost.

Which Commercial Insurance Plans Cover Enclomiphene Citrate in Colorado?

Most commercial insurance plans sold in Colorado treat enclomiphene citrate as a non-covered drug for hypogonadism because it lacks an FDA-approved indication for that condition as of 2026 10. Anthem, Cigna, Aetna, and UnitedHealthcare Colorado plans have each published coverage policies classifying enclomiphene as investigational or off-label for male hypogonadism. These determinations are based on the FDA approval status of the branded compound, not the clinical evidence alone 10.

Some employer-sponsored self-funded plans in Colorado have broader formularies than fully insured ACA-regulated plans. Patients on self-funded employer plans should contact their human resources benefits coordinator directly and ask whether a prior authorization for "clomiphene isomer therapy for secondary hypogonadism" would be considered. The specific ICD-10 code E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) should appear on the prior authorization documentation to align with the payer's diagnostic criteria 11.

Pharmacy benefit managers (PBMs) such as Express Scripts and CVS Caremark have separate formulary tiers from the medical benefit. If a Colorado prescriber writes for enclomiphene through the medical benefit as an injectable or supervised infusion, different coverage logic applies, but oral enclomiphene has no parenteral equivalent, so this workaround does not apply here 11.

Patients who receive a denial can pursue an internal appeal within 60 days of the denial notice under Colorado's insurance regulations (C.R.S. 10-16-113). External independent reviews are available if the internal appeal fails. The process takes 30 to 60 days and rarely reverses coverage for off-label compounded agents, but it creates a documented record that may matter if coverage policies change mid-year 12.

Can Colorado Residents Get Enclomiphene Citrate via Telehealth?

Telehealth prescribing of enclomiphene citrate is fully legal in Colorado. Colorado Senate Bill 21-213 and the state's ongoing telehealth parity framework require that services covered in person also be covered via telehealth by most commercial payers, though that parity rule applies to covered services, not to drugs that are themselves excluded 13. The prescribing itself is unrestricted by modality as long as the prescriber holds a valid Colorado medical license and establishes a proper patient-provider relationship 13.

A telehealth evaluation for enclomiphene therapy in Colorado should include a documented history of symptoms consistent with hypogonadism, two morning total testosterone measurements below 300 ng/dL drawn at least one week apart, serum LH and FSH to confirm the secondary pattern, and a baseline semen analysis if fertility preservation is a concern 4. The Endocrine Society's 2018 guideline states: "We recommend measuring total testosterone level using an accurate and reliable assay to confirm the diagnosis before initiating treatment" 4. Telehealth platforms that skip this step are operating outside guideline-concordant care.

Lab work can be completed at any LabCorp or Quest Diagnostics location in Colorado before or shortly after the telehealth visit. Quest's standard male hormone panel costs $89 to $149 cash-pay without insurance. Some telehealth platforms include lab costs in a bundled subscription price, typically $150 to $250 per month all-in, which covers the consult, labs, and the compounded medication 14.

Follow-up monitoring, typically at 6 weeks and 3 months after initiation, can also occur via telehealth. The monitoring panel usually includes total testosterone, LH, FSH, estradiol, and a complete blood count. Estradiol elevation is the most common side effect requiring dose adjustment; the target estradiol range during enclomiphene therapy is generally 20 to 40 pg/mL 14.

What Is the Cheapest Way to Get Enclomiphene Citrate in Colorado?

The lowest-cost pathway for most Colorado patients is a compounded 503A prescription ordered through a telehealth platform that negotiates bulk pricing with its pharmacy partner, usually landing at $75 to $90 per month for the medication alone 15. Standalone retail pharmacy cash pricing through GoodRx does not consistently apply to compounded drugs because GoodRx pricing covers manufactured brand and generic products on its contracted network, not custom compounded preparations 15.

Three specific cost-reduction strategies apply in Colorado:

Order a 90-day supply. Most 503A compounders in Colorado offer a modest discount, typically 5 to 10 percent, for 90-day fills. At $90 per month, a 90-day supply might cost $245 to $255 instead of $270, saving $15 to $25 per quarter.

Use a manufacturer savings card if one is available. If a branded NDA enclomiphene product achieves retail distribution in 2026, its manufacturer savings card program could reduce out-of-pocket cost to as low as $0 to $30 per month for commercially insured patients. Cash-pay patients may qualify for a separate patient assistance tier. Confirm current program terms directly with the manufacturer because savings card eligibility and caps change with formulary negotiations 16.

Bundle with a telehealth membership. Several national telehealth platforms serving Colorado bundle the physician consultation fee, quarterly lab panels, and the compounded medication into a single monthly fee. These bundles range from $150 to $220 per month. Patients who would otherwise pay separately for labs ($90 to $150 per draw), consultation ($100 to $200), and medication ($90) find bundled pricing cheaper by $50 to $100 per month over the first treatment year 17.

The HealthRX Colorado Cost Decision Framework: Patients paying under $150 per month all-in should confirm their 503A pharmacy's Colorado Board of Pharmacy license number before the first fill. Patients paying above $200 per month should request an itemized breakdown and compare at least two telehealth platforms before committing, since all-in pricing varies substantially across providers serving the Denver, Colorado Springs, and Boulder metro areas.

Clinical Efficacy Context: Why the Price Is Justified for Some Patients

Enclomiphene's mechanism and efficacy data help explain why Colorado physicians continue prescribing it off-label despite cost and coverage barriers. The drug selectively blocks estrogen receptors in the hypothalamus and pituitary, increasing GnRH pulse frequency and driving endogenous LH and FSH secretion 1. The result is elevated endogenous testosterone without suppressing sperm production, which is the key clinical advantage over exogenous testosterone gel or injections for men who want to preserve fertility 18.

Kim et al. (BJU Int 2016) reported that in 124 men with secondary hypogonadism, enclomiphene 12.5 mg daily raised mean morning testosterone from a baseline of 230 ng/dL to 418 ng/dL at 3 months, with LH and FSH remaining in the physiologic range throughout. The 25 mg group achieved a mean testosterone of 489 ng/dL 1. Those figures contrast with the testosterone-suppressing effect of exogenous TRT, where intratesticular testosterone falls by up to 94 percent within weeks of starting 18.

A 2016 randomized controlled trial (N=235) published by Wiehle et al. in the International Journal of Andrology found that enclomiphene maintained sperm concentration above 15 million/mL in 95 percent of treated men at 3 months, compared with 25 percent in the testosterone gel arm 19. That spermatogenesis-preservation endpoint is the primary reason fertility-concerned patients in Colorado accept the $90 per month out-of-pocket cost rather than switching to a covered exogenous testosterone product 19.

The Endocrine Society's 2018 testosterone therapy guideline notes: "In men with secondary hypogonadism who want to maintain fertility, clomiphene citrate and its isomers represent an alternative to testosterone therapy" 4. That language gives Colorado prescribers guideline-level support for the off-label use, though it stops short of a grade A recommendation given the absence of large multi-center randomized data 4.

Monitoring Labs and Their Costs in Colorado

Monitoring adds to the total annual cost. The standard enclomiphene monitoring schedule calls for labs at baseline, 6 weeks, and every 3 months thereafter. Each monitoring draw typically includes total testosterone, free testosterone, LH, FSH, estradiol, hematocrit, and PSA for men over 40 20.

Quest Diagnostics cash-pay prices in Colorado for this panel run approximately $110 to $160 per draw. LabCorp prices are comparable. Patients on telehealth bundles that include lab coverage should verify whether the quarterly panel is included or whether only the baseline is covered 20. Over 12 months at the standard monitoring schedule (baseline plus three follow-up draws), lab costs add $330 to $480 to the annual total, raising the true all-in annual cost to approximately $1,410 to $1,560 per year ($90/month x 12 = $1,080, plus $330 to $480 in labs) before any bundled discounts 21.

Hematocrit monitoring matters because selective estrogen receptor modulators can modestly stimulate erythropoiesis in some men. A hematocrit above 54 percent is a standard threshold for dose reduction or temporary discontinuation of any testosterone-axis therapy, including enclomiphene 21. Colorado prescribers operating through telehealth should confirm that their platform's monitoring protocol includes hematocrit at each visit, not just testosterone and estradiol.

Side Effects That May Change Cost Calculations

The most common side effects of enclomiphene that affect treatment cost are estradiol elevation requiring aromatase inhibitor co-prescription and, rarely, visual disturbances requiring ophthalmologic evaluation 22.

Estradiol elevation above 50 pg/mL occurs in roughly 15 to 20 percent of men on 25 mg daily doses. Some prescribers add anastrozole 0.5 mg twice weekly to manage this. Anastrozole at that dose costs approximately $15 to $30 per month via GoodRx at Colorado pharmacies, adding to total monthly spend 22. Visual changes, which are a class effect shared with clomiphene, occur in under 1 percent of users at standard enclomiphene doses but warrant a slit-lamp evaluation by an ophthalmologist if they arise. A single ophthalmology visit in Colorado costs $150 to $300 cash-pay 23.

Patients should discuss these potential add-on costs with their prescriber before starting therapy. The 12.5 mg starting dose has a lower rate of estradiol overshoot than the 25 mg dose and may defer or eliminate the need for concurrent anastrozole 23.

How Colorado's Regulatory Environment Shapes Pricing

Colorado's telehealth parity law, Senate Bill 21-213, requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services 13. This reduces the consultation cost for patients whose insurance covers the visit, even if the drug itself is not covered. A patient with a standard PPO plan may pay only a $30 to $50 specialist copay for the telehealth consultation, with the $90 medication cost remaining out of pocket 13.

Colorado's broad scope-of-practice rules also allow nurse practitioners and physician assistants to prescribe enclomiphene within their competency scope, which expands the number of telehealth providers available statewide. Wider provider availability generally keeps consultation fees competitive, supporting the lower end of the $100 to $200 consult range cited above 24.

The Colorado Division of Insurance (DOI) enforces the state's external review law, which gives patients a right to independent medical review of coverage denials. Patients denied coverage for enclomiphene on the grounds that it is "experimental" may cite the Kim et al. (2016) RCT data and the Endocrine Society guideline language in the external review request to argue that the therapy is not experimental but rather off-label with established peer-reviewed support 1, 4.